tert-butyl 4-(4-phenyl-1H-imidazole-1-yl)piperidine-1-carboxylate | 863257-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 4-(4-phenyl-1H-imidazole-1-yl)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(4-phenyl-1H-imidazol-1-yl)piperidine-1-carboxylate；1,1-dimethylethyl 4-(4-phenyl-1H-imidazol-1-yl)piperidine-1-carboxylate；tert-butyl 4-(4-phenylimidazol-1-yl)piperidine-1-carboxylate
• CAS: 863257-51-6
• 化学式: C₁₉H₂₅N₃O₂
• 分子量: 327.426
• InChiKey: HBQSVSBHCYFBMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-phenyl-1H-imidazole-1-yl)piperidine-1-carboxylate 在 N-溴代丁二酰亚胺(NBS) 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以900 mg的产率得到4-(5-Bromo-4-phenyl-1H-imidazol-1-yl)piperidine
  参考文献：
  名称：

  イミダゾール誘導体からなる医薬

  摘要：

  这段文字是关于一种具有对α7尼古丁性乙酰胆碱受体调节作用的化合物，可用于治疗中枢神经系统、外周神经系统的胆碱能疾病、内分泌疾病等，并提供相关药物的描述。解决方案是提供一种药物，其由式（Ｉ）表示的化合物或其药学上可接受的盐组成。【X-Y-Z代表CR6-CO-NR4AR4B等；R1代表苯基等；R2A和R2B代表H、卤素等；R3A至R3D和R6各自独立地代表H、Cl、氟化烷基，其中的两个是氟化烷基等；R4A或R4B代表H、芳香环、复杂芳香环、含4-10个饱和复杂环等；n为1或2】。【选择图】无。

  公开号：

  JP2015199722A
• 作为产物：
  描述：

  N-Boc-4-羟基哌啶 在 吡啶 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 tert-butyl 4-(4-phenyl-1H-imidazole-1-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  4-N-linked-heterocyclic piperidine derivatives with high affinity and selectivity for human dopamine D4 receptors

  摘要：

  The syntheses of a number of different N-linked heterocyclic pyrazole replacements based on the structure 1 are described (compounds 3-12) as hD4 ligands. After further optimisation the best compound identified was 13 which has high affinity for hD4 (5.2 nM) and >300-fold selectivity for hD4 receptors over hD2 and hD3 receptors. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00169-9

文献信息

• ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS
  申请人：ABOUABDELLAH Ahmed

  公开号：US20070021405A1

  公开（公告）日：2007-01-25

  The present invention comprises compounds corresponding to the general formula (I): in which m, n=1 to 3 and m+n=2 to 5; p=1 to 7; A=single bond or X, Y and/or Z; X=optionally substituted methylene; Y=C 2 -alkenylene, which is optionally substituted, or C 2 -alkynylene; Z=C 3-7 -cycloalkyl; R 1 represents a group of aryl or heteroaryl type; R 2 represents a hydrogen or fluorine atom or a hydroxyl, C 1-6 -alkoxy or NR 8 R 9 group; R 3 represents a hydrogen atom or a C 1-6 -alkyl group; R 4 represents a hydrogen atom or a C 1-6 -alkyl, C 3-7 -cycloalkyl or C 3-7 -cycloalkyl-C 1-3 -alkyl group; in the base form or in the form of an addition salt with an acid, of a hydrate or of a solvate. The compounds are useful in the treatment of a number of diseases and/or pathological conditions such as chronic pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases or urinary incontinence.

  本发明包括符合一般式（I）的化合物： 其中m、n = 1至3，m+n = 2至5；p = 1至7；A = 单键或X、Y和/或Z；X = 可选择取代的亚甲基；Y = 可选择取代的C2-烯基或C2-炔基；Z = C3-7-环烷基；R1表示芳香族或杂环芳族基团；R2表示氢或氟原子或羟基、C1-6-烷氧基或NR8R9基团；R3表示氢原子或C1-6-烷基基团；R4表示氢原子或C1-6-烷基、C3-7-环烷基或C3-7-环烷基-C1-3-烷基基团；以碱形式或与酸的加合盐形式、水合物形式或溶剂合物形式存在。这些化合物可用于治疗多种疾病和/或病理情况，如慢性疼痛、头晕、呕吐、恶心、进食障碍、神经和精神病理、急性或慢性神经退行性疾病、癫痫、睡眠障碍、心血管疾病、肾脏缺血、癌症、免疫系统紊乱、过敏性疾病、寄生虫、病毒或细菌感染性疾病、炎症性疾病、骨质疏松症、眼部疾病、肺部疾病、胃肠疾病或尿失禁。
• Azole compound
  申请人：Astellas Pharma Inc.

  公开号：US08207199B2

  公开（公告）日：2012-06-26

  A compound which is useful as an active ingredient of a pharmaceutical composition for treating neuropathic pain is provided. The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that an azole compound substituted with an N-(pyridine-3-yl)oxycarbonyl-piperidin-4-yl group and a phenyl group or a pharmaceutically acceptable salt thereof has an excellent FAAH inhibitory activity, thereby completing the present invention. The compound of the present invention is confirmed to have an excellent FAAH inhibitory activity and an antiallodynic effect in rat models with neuropathic pain, and thus is useful as an agent for preventing and/or an agent for treating neuropathic pain.

  提供了一种化合物，该化合物可作为制备用于治疗神经病性疼痛的药物组合物的活性成分。本发明人对具有FAAH抑制活性的化合物进行了广泛的研究，并发现一种咪唑化合物，其取代有N-(吡啶-3-基)氧羰基哌啶-4-基团和苯基，或其药学上可接受的盐具有出色的FAAH抑制活性，从而完成了本发明。本发明的化合物已被证实在神经病性疼痛的大鼠模型中具有出色的FAAH抑制活性和抗痛觉过敏作用，因此可用作预防和/或治疗神经病性疼痛的药剂。
• IMIDAZOLE DERIVATIVE
  申请人：DAINIPPON SUMITOMO PHARMA CO., LTD.

  公开号：US20150259344A1

  公开（公告）日：2015-09-17

  Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion disease, diseases associated with neuronal degeneration and the like, said therapeutic agent comprising a compound represented by Formula (I): [wherein X—Y—Z represents N—CO—NR 4A R 4B or the like; R 1 represents a phenyl group or the like; R 2A and R 2B may be the same as or different from each other and independently represent a hydrogen atom or the like; R 3A to R 3D and R 6 may be the same as or different from one another and independently represent a hydrogen atom or the like; R 4A and R 4B may be the same as or different from each other and independently represent an aryl group or the like; and n represents 1 or 2] or a pharmaceutically acceptable salt thereof and having a potent activity of regulating an α7 nicotinic acetylcholine receptor (an α7 nAChR).

  提供一种治疗剂，用于与中枢神经系统（CNS）和/或外周神经系统（PNS）的胆碱能性质相关的疾病、与平滑肌收缩相关的疾病、内分泌疾病、与神经退行性疾病等相关的疾病，所述治疗剂包括以下式（I）所表示的化合物：[其中X—Y—Z表示N—CO—NR4AR4B或类似物；R1表示苯基或类似物；R2A和R2B可以相同或不同，独立地表示氢原子或类似物；R3A到R3D和R6可以相同或不同，独立地表示氢原子或类似物；R4A和R4B可以相同或不同，独立地表示芳基或类似物；n表示1或2]或其药学上可接受的盐，具有调节α7尼古丁乙酰胆碱受体（α7 nAChR）的强效活性。
• AZOLE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2308869B1

  公开（公告）日：2012-09-19
• EP2905279
  申请人：——

  公开号：——

  公开（公告）日：——